Has novelty in the depression pipeline hit a wall?
The Phase III failure of another novel investigational product for depression, Shire's Vyvanse (lisdexamfetamine dimesylate), is raising questions over the health of the pipeline.
The Phase III failure of another novel investigational product for depression, Shire's Vyvanse (lisdexamfetamine dimesylate), is raising questions over the health of the pipeline.